Asset Details
Do you wish to reserve the book?
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Do you wish to request the book?
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
2012
Overview
Treatment with trametinib, a MEK inhibitor, resulted in significantly improved progression-free and overall survival, as compared with chemotherapy, in patients with advanced melanoma and activating BRAF mutations.
About 160,000 new cases of melanoma are diagnosed and 48,000 melanoma-related deaths occur worldwide each year.
1
Among cancers in patients under 40 years of age, the incidence of melanoma is second only to that of breast cancer for women and leukemia for men.
2
Before 2010, no systemic therapy had been shown to improve overall survival among patients with metastatic melanoma, and only modest improvements were observed with interferon as an adjuvant drug.
3
Ipilimumab, a monoclonal antibody targeting cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4), and vemurafenib, a selective BRAF inhibitor, have both been shown to improve survival among patients with metastatic melanoma . . .
Publisher
Massachusetts Medical Society
Subject
/ Aged
/ Antineoplastic Agents - adverse effects
/ Antineoplastic Agents - therapeutic use
/ Diarrhea
/ Edema
/ Female
/ Humans
/ Kinases
/ Male
/ MAP Kinase Kinase 1 - antagonists & inhibitors
/ MAP Kinase Kinase 2 - antagonists & inhibitors
/ Melanoma
/ Mutation
/ Protein Kinase Inhibitors - adverse effects
/ Protein Kinase Inhibitors - therapeutic use
/ Proto-Oncogene Proteins B-raf - genetics
/ Pyrimidinones - adverse effects
/ Pyrimidinones - therapeutic use
/ Skin
/ Survival
/ Tumors
